Tillkännagivande • Jul 30
FMC Corporation Provides Earnings Guidance for the Third Quarter, Fourth Quarter, Second Half of 2026 and Full Year 2026 FMC Corporation provided earnings guidance for the third quarter, fourth quarter, second half of 2026 and full year 2026. For the third quarter, the company expected revenue excluding India to be in the range of $840 million to $900 million.
For the fourth quarter, the company expects revenue to be in the range of $1.06 billion to $1.20 billion.
For the second half, the company expects revenue to be in the range of $1.90 billion to $2.10 billion.
For the year, the company expects revenue to be in the range of $3.50 billion to $3.70 billion, a decline of 7% at the midpoint versus prior year. Reported Earnings • Jul 30
Second quarter 2026 earnings released: US$1.54 loss per share (vs US$0.34 profit in 2Q 2025) Second quarter 2026 results: US$1.54 loss per share (down from US$0.34 profit in 2Q 2025). Revenue: US$867.1m (down 18% from 2Q 2025). Net loss: US$193.1m (down US$236.2m from profit in 2Q 2025). Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Chemicals industry in Italy. Tillkännagivande • Jul 24
Fmc Corporation Declares Quarterly Dividend, Payable on October 15, 2026 FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on October 15, 2026, to shareholders of record as of the close of business on September 30, 2026. Tillkännagivande • Jul 09
FMC Corporation Submits Regulatory Dossier for Rimisoxafen to United States Environmental Protection Agency FMC Corporation announced it has submitted the regulatory dossier for rimisoxafen to the United States Environmental Protection Agency, the first regulatory submission globally for this herbicide active ingredient. The U.S. submission covers use on corn, soybean, sunflower and select pulse crops. Rimisoxafen is the first herbicide active ingredient ever classified as a dual mode of action by the Global Herbicide Resistance Action Committee (HRAC). Designated under Groups 12 and 32, rimisoxafen inhibits two distinct biochemical pathways in weeds, which helps delay resistance development compared to single mode of action herbicides. Rimisoxafen is the third novel herbicide active ingredient FMC has advanced to regulatory submission in recent years, following Isoflex active and Dodhylex active. Together, these submissions reflect the depth and productivity of FMC's R&D pipeline and the company's commitment to advancing next-generation crop protection solutions through the regulatory process. FMC intends to pursue regulatory submissions for rimisoxafen in additional key geographies and crop segments as part of its global development program. Timing and outcomes are subject to regulatory review and approval in each jurisdiction. Rimisoxafen is not currently registered for sale or use in the United States or any other country. No offer for sale, sale or use of this product is permitted prior to receipt of all required regulatory approvals. Tillkännagivande • Jul 02
FMC Corporation announced that it expects to receive $400 million in funding from Tessenderlo Group NV FMC Corporation announced that it has entered into a definitive agreement with Tessenderlo Group NV for a minority stake invetment pursuant to which the company will issue 30,075,188 common shares at an issue price of $13.30 for gross proceeds of $400,000,000.4 on June 30, 2026. Upon completion of the transaction, Tessenderlo Group will own approximately 20.0% of the outstanding shares of FMC common stock. The closing of the transaction is subject to customary conditions, including the receipt of regulatory approvals. Tillkännagivande • Jun 23
FMC Corporation to Report Q2, 2026 Results on Jul 29, 2026 FMC Corporation announced that they will report Q2, 2026 results After-Market on Jul 29, 2026 Upcoming Dividend • Jun 22
Upcoming dividend of US$0.08 per share Eligible shareholders must have bought the stock before 29 June 2026. Payment date: 16 July 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Italian dividend payers (4.6%). Lower than average of industry peers (3.2%). Declared Dividend • May 02
Dividend of US$0.08 announced Shareholders will receive a dividend of US$0.08. Ex-date: 29th June 2026 Payment date: 16th July 2026 Dividend yield will be 1.6%, which is lower than the industry average of 2.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Reported Earnings • Apr 30
First quarter 2026 earnings released: US$2.09 loss per share (vs US$0.068 loss in 1Q 2025) First quarter 2026 results: US$2.09 loss per share (further deteriorated from US$0.068 loss in 1Q 2025). Revenue: US$758.6m (down 4.1% from 1Q 2025). Net loss: US$261.4m (loss widened US$252.9m from 1Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Chemicals industry in Italy. Tillkännagivande • Apr 29
FMC Corporation Declares Quarterly Dividend, Payable on July 16, 2026 FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026. Buy Or Sell Opportunity • Apr 21
Now 25% undervalued The stock has been flat over the last 90 days, currently trading at €13.54. The fair value is estimated to be €18.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • Apr 07
FMC Corporation Secures Approval for Isoflex Active in the European Union FMC Corporation announced that Isoflex active, the trade name for bixlozone, has received regulatory approval in the European Union (EU). This approval is a critical milestone in FMC's commercialization process, paving the way for the introduction of formulated products across more than 55 million planted hectares of cereals, corn, oilseed rape and potato in the EU. Product dossiers have been submitted for these crops, and pending regulatory decisions, FMC anticipates launching products powered by Isoflex active beginning in 2027. Isoflex active is classified by the Herbicide Resistance Action Committee (HRAC) as a Group 13 herbicide. The molecule provides lasting control of key grass weeds and a wide range of broadleaf weeds, offering growers a new mode of action in cereals, enabling them to effectively manage resistant weed populations and protect economically important crops across the EU. The European launches will build on FMC's global rollout of products powered by Isoflex active, which have already been registered and commercialized in Argentina, Australia, Brazil, Chile, China, Great Britain, Pakistan, Uruguay and India. Products containing Isoflex active have exhibited pre-plant, pre-emergence and early post-emergence selectivity in major crops across the globe, including cereals, cotton, oilseed rape, rice and pulses. Research and development on the use of Isoflex active in additional crops and segments is ongoing. Tillkännagivande • Mar 25
FMC Corporation to Report Q1, 2026 Results on Apr 29, 2026 FMC Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026 Upcoming Dividend • Mar 23
Upcoming dividend of US$0.08 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 16 April 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (3.7%). Recent Insider Transactions • Mar 08
Insider recently bought €215k worth of stock On the 4th of March, Michael Barry bought around 18k shares on-market at roughly €11.89 per share. This transaction increased Michael Barry's direct individual holding by 12x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €368k more in shares than they have sold in the last 12 months. Tillkännagivande • Feb 24
FMC Corporation Receives Industry's First Dual Mode of Action Herbicide Classification for Rimisoxafen FMC Corporation announced that the Herbicide Resistance Action Committee (HRAC) has classified rimisoxafen as a dual mode of action herbicide, designated under HRAC Groups 12 and 32. This is the first dual mode of action classification in HRAC's history, a significant milestone for the global crop protection industry and validation of FMC's innovative approach to combating herbicide-resistant weeds. The unprecedented classification recognizes rimisoxafen's unique ability to simultaneously inhibit both phytoene desaturase (PDS) and solanesyl diphosphate synthase (SDPS), two critical biochemical pathways in weeds. The dual mode of action makes it far more difficult for weeds to survive and adapt, providing a critical new tool in the fight against herbicide resistance. Herbicide resistance has become an increasingly serious challenge for global agriculture. Palmer amaranth, one of the most economically damaging weed threats facing growers, has developed resistance to eight different herbicide modes of action. Rimisoxafen's dual mode of action creates a significantly higher barrier to resistance development compared to single mode of action herbicides. Rimisoxafen is designed primarily for use in broadacre crops such as corn, soybean, cereals, pulses and sunflower, and will provide effective control of troublesome and resistant broadleaf weeds. Discovered by FMC scientists at the company's Stine Research Center, rimisoxafen represents the third novel herbicide that FMC has developed for regulatory submission in recent years, following Isoflex® active and Dodhylex™ active. FMC expects to begin submitting regulatory dossiers for rimisoxafen in key markets starting in 2026, marking the next step toward bringing this novel technology to growers in key global markets. Reported Earnings • Feb 05
Full year 2025 earnings released: US$17.59 loss per share (vs US$3.21 profit in FY 2024) Full year 2025 results: US$17.59 loss per share (down from US$3.21 profit in FY 2024). Revenue: US$3.47b (down 18% from FY 2024). Net loss: US$2.20b (down US$2.60b from profit in FY 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Chemicals industry in Italy. Tillkännagivande • Feb 05
FMC Corporation Provides Earnings Guidance for the First Quarter and Full Year 2026 FMC Corporation provides earnings guidance for the first quarter and full year 2026. For the quarter, the company expects revenue excluding India guidance is between $725 million and $775 million, a decline of 5 % at the midpoint versus prior year driven by a mid-single digit price headwind.
For the year, the company expects revenue excluding India guidance is $3.60 billion to $3.80 billion, a decline of 5 % at the midpoint versus prior year. Tillkännagivande • Jan 23
FMC Corporation, Annual General Meeting, Apr 28, 2026 FMC Corporation, Annual General Meeting, Apr 28, 2026. Tillkännagivande • Dec 23
FMC Corporation to Report Q4, 2025 Results on Feb 04, 2026 FMC Corporation announced that they will report Q4, 2025 results After-Market on Feb 04, 2026 Declared Dividend • Dec 17
Dividend of US$0.08 announced Shareholders will receive a dividend of US$0.08. Ex-date: 30th December 2025 Payment date: 15th January 2026 Dividend yield will be 9.6%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Tillkännagivande • Dec 13
FMC Corporation Declares Quarterly Dividend, Payable on January 15, 2026 FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on January 15, 2026, to shareholders of record as of the close of business on December 31, 2025. Tillkännagivande • Dec 05
FMC Corporation Announces Resignation of Anthony DiSilvestro from Board of Directors, Effective December 3, 2025 FMC Corporation announced that on December 3, 2025, Anthony DiSilvestro notified FMC Corporation of his resignation from the Board of Directors and all committees thereof, effective immediately, due to his increased professional commitments following his appointment as Chief Financial Officer of Keurig Dr Pepper Inc. on November 25, 2025, as well as scheduling conflicts with FMC Board and committee meeting dates. Reported Earnings • Oct 30
Third quarter 2025 earnings released: US$4.38 loss per share (vs US$0.53 profit in 3Q 2024) Third quarter 2025 results: US$4.38 loss per share (down from US$0.53 profit in 3Q 2024). Revenue: US$542.2m (down 49% from 3Q 2024). Net loss: US$548.9m (down US$614.6m from profit in 3Q 2024). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Chemicals industry in Italy. Buy Or Sell Opportunity • Oct 30
Now 42% undervalued after recent price drop Over the last 90 days, the stock has fallen 56% to €14.47. The fair value is estimated to be €24.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • Sep 26
FMC Corporation to Report Q3, 2025 Results on Oct 29, 2025 FMC Corporation announced that they will report Q3, 2025 results After-Market on Oct 29, 2025 Reported Earnings • Aug 04
Second quarter 2025 earnings released: EPS: US$0.34 (vs US$2.38 in 2Q 2024) Second quarter 2025 results: EPS: US$0.34 (down from US$2.38 in 2Q 2024). Revenue: US$1.05b (up 1.2% from 2Q 2024). Net income: US$43.1m (down 86% from 2Q 2024). Profit margin: 4.1% (down from 29% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Chemicals industry in Italy. Tillkännagivande • Aug 02
FMC Corporation Provides Earnings Guidance for the Third Quarter, Fourth Quarter and Second Half of 2025 and Reaffirms Earnings Guidance for the Full Year 2025 FMC Corporation provided earnings guidance for the third quarter, fourth quarter and second half of 2025 and reaffirmed earnings guidance for the full year 2025. For the third quarter, the company expects revenue to be in the range of $1.00 billion to $1.10 billion.
For the fourth quarter, the company expects revenue to be in the range of $1.24 billion to $1.34 billion.
For the second half, the company expects revenue to be in the range of $2.24 billion to $2.44 billion.
For the year, the company expects revenue to be in the range of $4.08 billion to $4.28 billion. Tillkännagivande • Aug 01
FMC Corporation Obtains Registration in Great Britain for Fundatis®? Herbicide Powered by Isoflex®? Active FMC Corporation announced it has received registration for Fundatis®? herbicide powered by Isoflex®? active in Great Britain for use in winter wheat and winter barley. Isoflex®? active is a novel herbicide when used in cereals and is classified by the Herbicide Resistance Action Committee (HRAC) as a Group 13 herbicide. Fundatis®? herbicide provides growers with a new tool to help manage herbicide resistance across a wide range of agronomic practices. Fundatis®? herb prevention combines FMC's innovative molecule Isoflex®? active with beflubutamid, providing growers with a new tool for resistance management. Fundatis®? herbicides provides a strong foundation as part of an integrated flower management program, effectively contributing to the control of key annual grass weeds, including Blackgrass (Alopecurus myosuroides) and Italian Ryegrass (Lolium multiflorum). It also offers control of key broadleaf weeds such as Groundsel (Senecio vulgaris) and Speedwell (Veronica spp.). Fundatis®? herbicide will be available to growers during the fall growing season in Great Britain. The registration in Great Britain marks another significant regulatory approval for FMC and Isoflex®? active, which has already been registered and commercialized in Argentina, Australia, Brazil, Chile, China, Pakistan, Uruguay and India. FMC has also submitted a regulatory application for Isoflex®? active In the European Union. Products containing Isoflex®? active have exhibited pre-plant, pre-emergence and early post-emergence selectivity in major crops across the globe, including canola, cereals, oilseed rape and pulses. Research on the use of Isoflex®? activein additional crops and segments is ongoing. Tillkännagivande • Jul 17
FMC Corporation Declares a Quarterly Dividend, Payable on October 16, 2025 FMC Corporation announced that its board of directors declared a regular quarterly dividend of 58 cents per share, payable on October 16, 2025, to shareholders of record as of the close of business on September 30, 2025. Tillkännagivande • Jul 01
FMC Corporation Expands Novel Fluindapyr Fungicide Technology to EMEA Region FMC Corporation announced regulatory approval for Tremisia fungicide in Ukraine, marking the first introduction of the company's novel fluindapyr technology in the European, Middle East, and Africa (EMEA) region. The approval covers oilseed rape, sunflower, and wheat across more than 10 million hectares of Ukrainian farmland. Tremisia fungicides combines FMC's proprietary fluindapyr molecule with flutriafol, delivering a dual mode of action to help maintain a healthy crop for an extended period. This fungicide targets a broad spectrum of economically significant diseases, including Alternaria and Sclerotinia in sunflower, and Septoria and rust in wheat. The Ukraine registration builds on FMC's successful commercialization of fluindapyr-based products in Argentina, Brazil, Mexico, Paraguay, South Korea, and the United States, with conditional approval secured in the Philippines earlier this year. Pending regulatory decisions, FMC anticipates launching fluindapyr-based product in Bolivia, Chile, Colombia, Honduras, and India, further expanding global access to this innovative fungicide technology. Tillkännagivande • Jun 20
FMC Corporation to Report Q2, 2025 Results on Jul 30, 2025 FMC Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025 
